Literature DB >> 11324865

Deficits in memory strategy use related to prefrontal dysfunction during early development: evidence from children with phenylketonuria.

D A White1, M J Nortz, T Mandernach, K Huntington, R D Steiner.   

Abstract

The prefrontal cortex has been implicated in the mediation of executive processes that facilitate learning and memory. The authors hypothesized that children with prefrontal dysfunction related to phenylketonuria (PKU) would experience deficits in learning and memory because of impaired strategy use. They evaluated 23 children with PKU and 23 controls by using the California Verbal Learning Test-Children's Version (CVLT-C). General executive abilities were tested using the Stroop Color and Word Test, the Wisconsin Card Sorting Test, and phonemic and category fluency. Children with PKU, especially older children, showed poorer learning across trials and less use of semantic clustering on the CVLT-C but intact retention of previously encoded information. With the exception of phonemic fluency, deficits were not observed in general executive control. Results are discussed within the context of abnormalities in the prefrontal cortex and white matter of the brain.

Entities:  

Mesh:

Year:  2001        PMID: 11324865     DOI: 10.1037//0894-4105.15.2.221

Source DB:  PubMed          Journal:  Neuropsychology        ISSN: 0894-4105            Impact factor:   3.295


  16 in total

Review 1.  Sequential memory: a developmental perspective on its relation to frontal lobe functioning.

Authors:  Cassandra Burns Romine; Cecil R Reynolds
Journal:  Neuropsychol Rev       Date:  2004-03       Impact factor: 7.444

2.  Tackling frontal lobe-related functions in PKU through functional brain imaging: a Stroop task in adult patients.

Authors:  Benedikt Sundermann; Bettina Pfleiderer; Harald E Möller; Wolfram Schwindt; Josef Weglage; Jöran Lepsien; Reinhold Feldmann
Journal:  J Inherit Metab Dis       Date:  2011-04-14       Impact factor: 4.982

3.  Effects of dietary management of phenylketonuria on long-term cognitive outcome.

Authors:  Shelley Channon; Galya Goodman; Sally Zlotowitz; Caroline Mockler; Philip J Lee
Journal:  Arch Dis Child       Date:  2006-10-26       Impact factor: 3.791

4.  Developmental Trajectories of Executive and Verbal Processes in Children with Phenylketonuria.

Authors:  Zoë W Hawks; Michael J Strube; Neco X Johnson; Dorothy K Grange; Desirée A White
Journal:  Dev Neuropsychol       Date:  2018-02-12       Impact factor: 2.253

5.  Neuropsychological outcome of subjects participating in the PKU adult collaborative study: a preliminary review.

Authors:  V L Brumm; C Azen; R A Moats; A M Stern; C Broomand; M D Nelson; R Koch
Journal:  J Inherit Metab Dis       Date:  2004       Impact factor: 4.982

6.  Developmental timing of exposure to elevated levels of phenylalanine is associated with ADHD symptom expression.

Authors:  Kevin M Antshel; Susan E Waisbren
Journal:  J Abnorm Child Psychol       Date:  2003-12

7.  Response monitoring in children with phenylketonuria.

Authors:  Gabriel C Araujo; Shawn E Christ; Robert D Steiner; Dorothy K Grange; Binyam Nardos; Robert C McKinstry; Desirée A White
Journal:  Neuropsychology       Date:  2009-01       Impact factor: 3.295

Review 8.  The truth of treating patients with phenylketonuria after childhood: the need for a new guideline.

Authors:  F J van Spronsen; P Burgard
Journal:  J Inherit Metab Dis       Date:  2008-08-12       Impact factor: 4.982

9.  Single-dose, subcutaneous recombinant phenylalanine ammonia lyase conjugated with polyethylene glycol in adult patients with phenylketonuria: an open-label, multicentre, phase 1 dose-escalation trial.

Authors:  Nicola Longo; Cary O Harding; Barbara K Burton; Dorothy K Grange; Jerry Vockley; Melissa Wasserstein; Gregory M Rice; Alejandro Dorenbaum; Jutta K Neuenburg; Donald G Musson; Zhonghua Gu; Saba Sile
Journal:  Lancet       Date:  2014-04-14       Impact factor: 79.321

10.  White matter integrity and executive abilities in individuals with phenylketonuria.

Authors:  Jo Ann V Antenor-Dorsey; Tamara Hershey; Jerrel Rutlin; Joshua S Shimony; Robert C McKinstry; Dorothy K Grange; Shawn E Christ; Desirée A White
Journal:  Mol Genet Metab       Date:  2013-04-06       Impact factor: 4.797

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.